Why AI matters at this scale

Bausch + Lomb is a global leader in eye health, providing a comprehensive portfolio of contact lenses, lens care products, pharmaceuticals, intraocular lenses, and other surgical equipment. Founded in 1853, the company operates at a massive scale, with over 10,000 employees and a presence in nearly 100 countries. Its business spans high-stakes R&D for new drugs and materials, precision manufacturing, and a mix of B2B and direct-to-consumer sales.

For an enterprise of this size and sector, AI is not a novelty but a strategic imperative. The pharmaceutical and medical device industry is characterized by long, expensive development cycles, stringent regulatory oversight, and intense competition. AI offers levers to compress R&D timelines, optimize billion-dollar manufacturing operations, and personalize engagement in crowded markets like contact lenses. At Bausch + Lomb's scale, even a single-digit percentage improvement in R&D efficiency or manufacturing yield translates to tens of millions in annual savings and accelerated delivery of sight-saving products.

Concrete AI Opportunities with ROI Framing

1. Accelerating Ophthalmic Drug Discovery: The traditional drug discovery pipeline can take over a decade and cost billions. By deploying generative AI and machine learning on molecular and historical trial data, Bausch + Lomb can rapidly simulate and screen thousands of novel compounds for conditions like glaucoma or dry eye. This can shrink the early discovery phase from years to months, reducing associated R&D burn rate and creating a pipeline advantage. The ROI is measured in faster time-to-market for blockbuster drugs and reduced capital tied up in failed candidates.

2. Enhancing Manufacturing Precision and Uptime: The company's factories produce sensitive medical devices like intraocular lenses and contact lenses, where micron-level defects are unacceptable. AI-driven computer vision can perform real-time, hyper-accurate quality inspections far surpassing human capability, dramatically reducing scrap rates and recall risks. Furthermore, predictive maintenance AI on production line machinery can forecast failures before they happen, minimizing costly unplanned downtime. The direct ROI here is clear: higher yield, lower waste, and increased overall equipment effectiveness (OEE).

3. Personalizing the Eyecare Journey: Through its contact lens subscription services and consumer products, Bausch + Lomb gathers vast amounts of customer data. AI can analyze this data to predict individual needs—recommending specific lens types based on lifestyle, automating reorder reminders, or even suggesting complementary eye wellness products. This drives higher customer lifetime value (CLV) through increased retention and cross-selling, while AI-optimized logistics can ensure perfect inventory availability, boosting margins.

Deployment Risks Specific to a 10,000+ Enterprise

Implementing AI at this scale brings unique challenges. Integration Complexity is paramount; weaving new AI tools into a sprawling, often fragmented landscape of legacy ERP (like SAP), CRM, and manufacturing execution systems requires significant IT resources and can stall projects. Data Silos are endemic in large organizations; unlocking R&D, clinical, and commercial data for AI training demands robust data governance and engineering efforts. Regulatory Hurdles are extreme; any AI used in product development or manufacturing must be rigorously validated to meet FDA and global health authority standards, adding time and cost. Finally, Change Management across tens of thousands of global employees requires careful planning to build internal AI literacy and avoid workforce disruption.